Background According to the Japanese Esophageal Society (JES) guidelines, risk factors for lymph node (LN) metastasis in the muscularis mucosa (MM)/submucosa to a depth of up to 200 μm (SM1) in cases of esophageal squamous cell carcinomas (ESCCs) include the presence of lymphatic invasion (ly), venous invasion (v), infiltration pattern (INF)c, and SM1. The long-term prognoses of these patients are unclear, and there are very few reports on the validation of the curative criteria for MM/SM1 ESCCs. Aims To examine the long-term prognoses of these patients and the risk factors for LN metastasis of MM/SM1 ESCCs after endoscopic resection (ER). Methods This study included patients with MM/SM1 ESCCs who underwent ER at Hiroshima University Hospital from December 1990 to November 2016. We evaluated the clinicopathological characteristics of 98 patients and overall survival, disease-specific survival, recurrence-free survival, and recurrence rates in the e-curative and non-e-curative groups. Results The mean observation period was 75 months. There was no significant difference in disease-specific survival rate between the e-curative and non-e-curative groups (100 vs. 98%). There was no significant difference in disease-specific survival rates between the groups (100 vs. 98%). In contrast, the LN recurrence-free survival rate in patients with INFa, ly(−), and v(−) was significantly higher than that in patients with INFb/c, ly(+), or v(+) (100 and 87%, P < 0.05). Conclusion Contrary to the JES guidelines, our findings suggest that new criteria (MM/SM1, INFa, negative vertical margin (VM0), ly [-], and v [-]) may be associated with curative ER without additional treatment.
Introduction
Esophageal squamous cell carcinomas (ESCCs) have among the worst prognoses of all carcinomas. The overall 5-year survival rate for advanced-stage ESCC patients is around 10-20%, and treatment often involves modern surgical techniques and/or chemoradiotherapy (CRT). Endoscopic resection (ER) is used for gastrointestinal cancers and superficial ESCCs. Endoscopic mucosal resection (EMR) is a minimally invasive technique used mainly for the treatment of ESCCs, and several studies have reported the indications, risks, and prognoses of the ESCC following EMR [1] [2] [3] [4] . However, the presence of residual esophageal mucosa after EMR is associated with the metachronous ESCC. Endoscopic submucosal dissection (ESD) is a common treatment for gastrointestinal neoplasms, including ESCCs [5] [6] [7] . ESD has a higher curative rate than conventional EMR for 1 3 ESCCs. Accurate pathological evaluation has become possible in recent years [8] . Recently, studies have reported the short-and long-term outcomes for ESCC after ER, including ESD [9] [10] [11] [12] [13] [14] [15] .
ER is used for ESCCs confined to the epithelium and lamina propria (EP/LPM) because lymph node (LN) metastasis is extremely rare in these lesions [16] [17] [18] [19] . In contrast, ESCCs that invade the muscularis mucosa (MM) or submucosa (up to 200 μm) (SM1) have an LN metastasis rate of approximately 10% [20] . ER is indicated in these patients.
According to the third Japanese Esophageal Society (JES) guidelines (2012) [21, 22] , risk factors for LN metastasis in MM/SM1 ESCCs include the presence of lymphatic invasion (ly), venous invasion (v), infiltration pattern (INF)c (i.e., a scattered infiltration pattern), and SM1. In these guidelines, patients in the endoscopically curative (e-curative) group have en bloc resected lesions with pathologically confirmed MM, INFa/b, vertical margin (VM)0, ly(−), or v(−), and can be followed up without additional treatment [22] . Patients with piecemeal resected and/or SM1 lesions, which require further treatment, are included in the non-e-curative group [22] .
The long-term prognoses of these patients are unclear, and there are very few reports on the validation of the curative criteria for MM/SM1 ESCCs. With this in mind, this study aimed to investigate the long-term prognoses of these patients and the risk factors for LN metastasis of MM/SM1 ESCCs after ER.
Materials and Methods

Patients
We performed EMR for 403 ESCCs in 324 patients and ESD for 785 ESCCs in 611 patients at Hiroshima University Hospital from December 1990 to November 2016. We included patients with MM/SM1 ESCCs who underwent ER. These patients underwent additional treatment and/or surveillance in accordance with the JES guidelines [21, 22] . We evaluated the clinicopathological characteristics of the patients and also the overall survival, disease-specific survival, recurrence-free survival, LN recurrence, and local recurrence rates in both groups.
ER Procedure
For EMR and ESD, each patient was placed in a left lateral position, and the operator and assistant stood on the left side of the examination table in front of the patient. A single-channel endoscope (GIF-Q260 J or H260Z; Olympus, Tokyo, Japan or EG-450RD5 or EG-590WR; FUJIFILM, Tokyo, Japan) or two-channel endoscope (GIF-2TQ260M; Olympus) was used for conventional endoscopic observation.
For EMR, local injection was performed from the distal side. The injection solution consisted of a 10% glycerin solution with 0.025% epinephrine and 0.005% indigo carmine. The solution was injected under the epithelium to produce an adequate elevation cushion. Lesions were removed using a Snare Master (Olympus).
For ESD, the circumference of the lesion was marked with argon plasma coagulation. Local injection and incision were first performed from the distal side. The marks were checked, and the elevated area was incised with a hook knife (Olympus) in the VIO300D cut mode. Injection and incision were repeated from the proximal side, extending the incision circumferentially around the entire lesion. A soft, transparent hood was attached to the tip of the endoscope before incision to achieve adequate tension for dissection. A hook knife, IT knife nano, Dual knife (Olympus), and/or SB knife (Sumitomo Bakelite, Tokyo, Japan) was used to exfoliate the submucosa in the VIO300D cut or coagulation mode. Injection of 10% glycerin solution and sodium hyaluronate with 0.0025% epinephrine into the submucosa was performed as needed, and further resection was performed to ensure total lesion removal.
Pathological Examination
Resected specimens were stretched, pinned to polystyrene foam boards, and fixed in 10% formalin for 24 h. All resected specimens were cut into 2-mm-wide longitudinal slices and embedded in paraffin, sectioned at 4 mm, and stained with hematoxylin and eosin. Histological evaluation was performed by two experienced pathologists.
Surveillance After ER
Follow-up surveillance endoscopy was performed at our hospital and an affiliated hospital 3-12 months after ER according to the type of resection. In patients with e-curative ER, endoscopic examination was performed 12 months after the procedure and once every 12 months thereafter. In patients with non-e-curative ER, endoscopic examination was performed 3, 6, and 12 months after the procedure during the first year and every 12 months thereafter. A tumor detected in close proximity to the scar resulting from ER was regarded as a locally recurrent tumor, whereas ≥ 1 primary tumors detected > 1 cm from the ER scar were regarded as metachronous tumors. Computed tomography (CT) was performed annually to detect the LN or metastasis in other organs. Surgery or radiotherapy (RT) was employed as additional treatments after ER until 2001. After 2002, surgery or chemoradiotherapy (CRT) was performed [23, 24] . RT was performed by external beam radiotherapy with 50-58 Gy/25-29 fractions (median 54 Gy) and intraluminal brachytherapy boost 10 Gy/4 fractions. For CRT, RT at a median dose of 60 Gy/30 fractions (range, 54-66 Gy) with elective nodal irradiation of 40 Gy was combined concurrently with 5-fluorouracil-based chemotherapy [24] .
Additional Treatment
Ethical Approval
This study was conducted with approval from the Institutional Review Board of Hiroshima University. Informed consent was obtained from all patients.
Statistical Analysis
Values are shown as means ± standard deviations (SDs). Statistically significant differences were evaluated using Student's t test, the Chi-square test and Fisher's exact probability test as appropriate. Survival analyses were performed using Kaplan-Meier analyses. A P value < 0.05 was considered statistically significant. JMP version 12 (SAS Institute, Cary, USA) was used for all statistical analyses.
Results
Patients
This study included 98 patients with MM/SM1 (76 MM and 22 SM1) ESCCs who underwent ER (EMR: 59, ESD: 39). The clinicopathological features of these patients are shown in Table 1 . Thirty-nine patients underwent e-curative ER and 59 underwent non-e-curative ER. The reasons for non-e-curative ER were as follows: piecemeal resection (39 patients), SM1 invasion (22 patients), ly(+) (17 patients), INFc (eight patients), and v(+) (two patients) (some overlaps). There were no significant differences in age, sex, tumor location, macroscopic type, and tumor diameter between the groups. Additional treatment was performed for 9 of 39 (23%) patients with curative ER and for 39 of 59 (66%) patients with non-e-curative ER.
Outcomes of ER
The outcomes of ER are shown in Fig. 1 
Survival Rates
The overall survival rates of patients with MM/SM1 ESCCs are shown in Fig. 2 . The mean observation period was 75 months (SD, 44 months). The 5-year overall survival rate was significantly higher in the e-curative group than in the non-e-curative group (97 vs. 75%, P < 0.05). In the non-ecurative group, three deaths (10%) occurred due to primary cancer. The other causes were as follows: cancer of other organs (nine patients), heart failure (four patients), pneumonia (three patients), and other reasons (11 patients). In the e-curative group, no deaths occurred due to primary cancer. The other causes of death were cancer in other organs (two patients) and other reasons (three patients).
The disease-specific survival rates of patients with MM/ SM1 ESCCs are shown in Fig. 3 . There was no significant difference in disease-specific survival between the two groups (100 vs. 98%). No patients died from ESCC in the e-curative ER group. LN recurrence-free survival rates in the non-e-curative group are shown in Fig. 4 . There was no significant difference between the two groups.
Patients with LN and local recurrence are given in Table 3 . Four of five patients with LN recurrence were included in the non-e-curative group, and the remaining patient was in the e-curative group. One patient with LN recurrence in the e-curative group underwent en bloc resection with pathological MM, INFb, HMx, VM0, ly(−), and v(−). Four patients with local recurrence underwent piecemeal EMR. The LN recurrence rates in the e-curative and non-e-curative groups were 3% (1/39) and 7% (4/59), respectively. The local recurrence rates in the e-curative and non-ecurative groups were 0% (0/39) and 7% (4/59), respectively.
The 5-year LN recurrence-free survival rates in the e-curative and non-e-curative groups were 97 and 98%, respectively (Fig. 5) . There was no significant difference between the groups. The LN recurrence-free survival rate in patients with INFa, ly(−), and v(−) was significantly higher than that in patients with INFb/c, ly(+), or (v +) (100 and 87%, P < 0.05) (Fig. 6) . Fig. 1 Outcomes of 98 patients with esophageal squamous cell carcinoma with submucosa/muscularis mucosa metastasis
Discussion
The findings of this study suggest that MM/SM1, INFa, VM0, ly(−), and v(−) MM/SM1 ESCCs may be cured after ER without additional treatment. Several previous reports have shown that survival after EMR in patients with MM/SM1 ESCCs does not differ significantly to survival in surgically treated patients [4, 25] . In the present study, there was no difference in disease-specific survival between the two groups determined according to the JES guidelines (Fig. 3) . However, many researchers have reported that MM/SM1 ESCCs are associated with a 10% rate of LN metastasis [26] . In addition, the disease-specific survival rate in the non-e-curative group was lower than that in the e-curative group. Furthermore, the difference in rates between the two groups increased with longer observation periods. If the number of enrolled patients was larger, a significant difference may have been detected. It may be risky to treat all MM/SM1 ESCCs with only ER because it cannot treat LN metastasis.
The identification of risk factors for metastasis is an urgent goal for reducing unnecessary additional treatment, Invasion depth, lymphovascular invasion [26] , INFc [27] , and poorly differentiated-type lesions [28] have been reported as risk factors. Based on this evidence, the JES published their criteria for e-curative ER. However, we could not confirm the clinical validity of the JES guidelines (Fig. 5) given that the LN recurrence-free survival rate in patients with e-curative ER did not differ significantly from that in patients with non-e-curative ER. This may be due to the relatively limited number of patients, selection bias, and/or technical bias. Even in the e-curative group, 3% (1/39) of patients had LN metastasis. Because LN metastasis was observed in the e-curative group, we propose that new criteria for e-curative are needed. Our data suggest that patients with pathological MM/SM1, INFa, VM0, ly(−), and v(−) had no LN metastasis and significantly better prognoses than other patients (Fig. 6) . A longer follow-up period would have been ideal. In addition, further prospective examinations in a multicenter study are needed to validate these new criteria.
In the present study, the overall survival rate was significantly lower in the non-e-curative group than that in the e-curative group (Fig. 2) . In the non-e-curative group, more deaths due to causes other than the primary cancer were observed than in the e-curative group. There may be some associations between the patient's general condition and ER quality. For example, when a patient's general condition was suboptimal, adequate levels of sedation could not be achieved. This may have resulted in lower-quality ER because of the patient's body movements and/or pain. However, these issues could simply be the result of variations between patients. Abbreviations as in Fig. 2 The e-curative criteria defined by the JES guidelines do not include the factor of horizontal margin (HM). According to the JES guidelines, although the horizontal margin after ER is not negative, additional treatment is not needed because the tumor may vanish by the burning effect. Careful observation by endoscopy 3-6 monthly is recommended. Therefore, our new criteria do not include the HM factor. Of course, endoscopically HM0 is a presupposition.
There was recurrence of LN metastasis even in longterm follow-up cases of over 5 years. Additionally, patients with multiple Lugol-voiding lesions of the esophagus also carry the risk of metachronous multifocal ESCC [29, 30] . It is important to continue CT scanning and surveillance endoscopy within half a year after ER of MM/SM1 ESCC as often as possible.
During the study period, the regimen for additional treatment changed from RT to CRT. This was because the prognosis of patients with RT had not been favorable (Fig. 3) . After changing to CRT, the patients' prognoses improved. Kato et al. reported a high complete remission rate and good survival rate for stage-MM/SM1 ESCC patients with CRT using 5-fluorouracil plus cisplatin [31] . Recently, Muto et al. reported the efficacy and safety of combined treatment using ER and CRT for stage-MM/ SM1 ESCC patients (JCOG0508) [32] . These data suggest that ER plus CRT may represent the new standard treatment instead of surgery for patients with non-e-curative MM/SM1 ESCCs.
The present study had several limitations. First, this was a retrospective and single-center study. Second, the selection criteria for additional treatments were not uniform and depended on the discretion of the physicians in charge. Therefore, treatment bias may be present. Third, two methods of ER (EMR and ESD) were applied in the present study. The choice mainly depended on the period treatment was done. ESD has been performed since 2006, while EMR had been performed before 2006. ESD is associated with higher rates of en bloc resection than EMR. Therefore, a significantly higher number of e-curative patients underwent ESD in the present study (Table 2 ).
In conclusion, the results of the present study suggest that some new criteria, namely MM/SM1, INFa, VM0, ly(−), and v(−), may be associated with curative ER without additional treatment in patients with MM/SM1 ESCCs following ER. These findings contradict the JES guidelines. These findings should be validated in future prospective, multicenter studies.
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